FDA Grants Priority Review of Ixabepilone Plus Two Other Agents

Publication
Article
OncologyONCOLOGY Vol 21 No 8
Volume 21
Issue 8

The US Food and Drug Administration (FDA) has accepted, for filing and priority review, the New Drug Application (NDA) for Bristol-Myers Squibb's investigational compound ixabepilone, an epothilone B analog.

The US Food and Drug Administration (FDA) has accepted, for filing and priority review, the New Drug Application (NDA) for Bristol-Myers Squibb's investigational compound ixabepilone, an epothilone B analog. The proposed indications for ixabepilone are as a monotherapy to treat patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine (Xeloda) and in combination with capecitabine to treat patients with metastatic or locally advanced breast cancer after failure of an anthracycline and a taxane. Currently, there are few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or whose disease is not responding to prior treatment with chemotherapies.

Oral Topotecan for Relapsed Small-Cell Lung Cancer

GlaxoSmithKline announced that its NDA for oral topotecan (Hycamtin) capsules, a treatment for relapsed small-cell lung cancer (SCLC), has also been granted priority review by the FDA. This application was based on encouraging results from a phase III study comparing oral topotecan plus best supportive care (BSC) to BSC alone in patients with relapsed SCLC, in addition to two phase II and phase III supporting studies. Unlike IV topotecan, which requires 5 consecutive days of intravenous therapy every 3 weeks, oral topotecan will allow patients to be treated at home.

Cetuximab and Overall Survival in Advanced Colorectal Cancer

ImClone Systems and Bristol-Myers Squibb announced that the FDA has granted priority review to a supplemental biologics license application (sBLA) for cetuximab (Erbitux). With this application, the companies seek to include evidence of improved overall survival in the product labeling for cetuximab in the third-line treatment of patients with metastatic colorectal cancer. If the sBLA is approved, cetuximab would be the only biologic therapy to demonstrate improved overall survival as a single agent in patients with metastatic colorectal cancer.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.